Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial

Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial

Abstract Background Normofractionated radiation regimes for definitive prostate cancer treatment usually extend over 7–8 weeks. Recently, moderate hypofractionation with doses per fraction between 2.2 and 4 Gy has been shown to be safe and feasible with oncologic non-inferiority compared to normofra...

Full description

Bibliographic Details
Main Authors: J. Ristau, J. Hörner-Rieber, C. Buchele, S. Klüter, C. Jäkel, L. Baumann, N. Andratschke, H. Garcia Schüler, M. Guckenberger, M. Li, M. Niyazi, C. Belka, K. Herfarth, J. Debus, S. A. Koerber
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Radiation Oncology
Subjects:
Prostate cancer
SBRT
Ultrahypofractionation
MR guided radiotherapy
Adaptive radiotherapy
SIB
Online Access:https://doi.org/10.1186/s13014-022-02047-w

Internet

https://doi.org/10.1186/s13014-022-02047-w

Similar Items